Shortsea shipping specialist CLdN if offering a pooling service to allow shipping industry stakeholders to meet more rigorous ...

2025年有望获批的ADC药物备受瞩目。 国产抗肿瘤ADC在数量上领跑，其中CLDN-18.2 ADC和B7-H3 ADC药物竞争尤为激烈。信达生物、阿斯利康/乐普/康诺亚、恒瑞、礼新医药的四款CLDN-18.2 ...

Tidal Transit and HICO secure equity funding for six new-build electric vessels. Find the latest news from the maritime ...

CLdN offers pooling services to support FuelEU Maritime compliance. Find the latest news from the maritime industry on the PortNews website.

Bunkerspot provides news, in-depth analysis, expert comment and price indications for the global marine fuels industry ...

Shipowner CLdN has launched a pooling venture to partner with peers in meeting new European Union rules on greenhouse gas ...

Mab’s pipeline pivot had a sting in the tail. Weeks after shifting its focus, the biotech said Wednesday that it has reduced its workforce by around 27% in conjunction with the pipeline ...

Findings from this survey also demonstrated that 23% of providers were comfortable with interpreting biomarker testing results for treatment decision-making.

1 月 22 日，乐普生物宣布，与 ArriVent BioPharma, Inc. 就针对 消化道癌的潜在同类最佳抗体偶联药物 MRG007达成全球独家许可协议。根据协议，乐普生物授予 ArriVent 在大中华区 （包括中国大陆、中国香港、中国澳门和中国台湾）以外地区开发、制造和商业化 MRG007 的全球独家许可。作为回报，乐普生物将获得总计 4700 ...

Antennova, a clinical-stage biotech company focused on oncology today announced the presentation of latest data from its Phase I/II CLINCH study ongoing in China and Australia evaluating ATN-022 ...

1月15日，Axcynsis Therapeutics Pte ...